Drug
EXPAREL® infiltration
EXPAREL® infiltration is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_4
3
75%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Terminated1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 43 (100.0%)
Trials by Status
terminated125%
withdrawn125%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_4
Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty
NCT02284386
completedphase_4
EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty
NCT02255500
withdrawn
Post-Operative Pain Management Following Spine Surgery
NCT03076710
terminatedphase_4
Exparel in Minimally Invasive Cardiac Surgery
NCT02008370
Clinical Trials (4)
Showing 4 of 4 trials
NCT02284386Phase 4
Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty
NCT02255500Phase 4
EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty
NCT03076710
Post-Operative Pain Management Following Spine Surgery
NCT02008370Phase 4
Exparel in Minimally Invasive Cardiac Surgery
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4